JP4932112B2 - 診断及び治療用エピトープ並びにトランスジェニック植物 - Google Patents

診断及び治療用エピトープ並びにトランスジェニック植物 Download PDF

Info

Publication number
JP4932112B2
JP4932112B2 JP2001528704A JP2001528704A JP4932112B2 JP 4932112 B2 JP4932112 B2 JP 4932112B2 JP 2001528704 A JP2001528704 A JP 2001528704A JP 2001528704 A JP2001528704 A JP 2001528704A JP 4932112 B2 JP4932112 B2 JP 4932112B2
Authority
JP
Japan
Prior art keywords
gliadin
peptide
cells
celiac disease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001528704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511670A (ja
JP2003511670A5 (enExample
Inventor
アンダーソン,ロバート,ポール
ヒル,エイドリアン,ビビアン,シントン
ジュエル,デレク,パリー
Original Assignee
アイシス イノヴェイション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイシス イノヴェイション リミテッド filed Critical アイシス イノヴェイション リミテッド
Publication of JP2003511670A publication Critical patent/JP2003511670A/ja
Publication of JP2003511670A5 publication Critical patent/JP2003511670A5/ja
Application granted granted Critical
Publication of JP4932112B2 publication Critical patent/JP4932112B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
JP2001528704A 1999-10-01 2000-10-02 診断及び治療用エピトープ並びにトランスジェニック植物 Expired - Lifetime JP4932112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9923306.6A GB9923306D0 (en) 1999-10-01 1999-10-01 Diagnostic and therapeutic epitope, and transgenic plant
GB9923306.6 1999-10-01
PCT/GB2000/003760 WO2001025793A2 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010135844A Division JP5371890B2 (ja) 1999-10-01 2010-06-15 診断及び治療用エピトープ並びにトランスジェニック植物

Publications (3)

Publication Number Publication Date
JP2003511670A JP2003511670A (ja) 2003-03-25
JP2003511670A5 JP2003511670A5 (enExample) 2007-11-22
JP4932112B2 true JP4932112B2 (ja) 2012-05-16

Family

ID=10861989

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001528704A Expired - Lifetime JP4932112B2 (ja) 1999-10-01 2000-10-02 診断及び治療用エピトープ並びにトランスジェニック植物
JP2010135844A Expired - Lifetime JP5371890B2 (ja) 1999-10-01 2010-06-15 診断及び治療用エピトープ並びにトランスジェニック植物
JP2013018731A Expired - Lifetime JP6139154B2 (ja) 1999-10-01 2013-02-01 診断及び治療用エピトープ並びにトランスジェニック植物
JP2016053617A Pending JP2016164169A (ja) 1999-10-01 2016-03-17 診断及び治療用エピトープ並びにトランスジェニック植物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010135844A Expired - Lifetime JP5371890B2 (ja) 1999-10-01 2010-06-15 診断及び治療用エピトープ並びにトランスジェニック植物
JP2013018731A Expired - Lifetime JP6139154B2 (ja) 1999-10-01 2013-02-01 診断及び治療用エピトープ並びにトランスジェニック植物
JP2016053617A Pending JP2016164169A (ja) 1999-10-01 2016-03-17 診断及び治療用エピトープ並びにトランスジェニック植物

Country Status (14)

Country Link
US (5) US7144569B1 (enExample)
EP (2) EP1672368B1 (enExample)
JP (4) JP4932112B2 (enExample)
AT (2) ATE449965T1 (enExample)
AU (1) AU782262B2 (enExample)
CA (1) CA2386089C (enExample)
CY (2) CY1105282T1 (enExample)
DE (2) DE60043402D1 (enExample)
DK (2) DK1672368T3 (enExample)
ES (2) ES2335895T3 (enExample)
GB (1) GB9923306D0 (enExample)
MX (1) MXPA02003295A (enExample)
PT (2) PT1218751E (enExample)
WO (1) WO2001025793A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013126991A (ja) * 1999-10-01 2013-06-27 Isis Innovation Ltd 診断及び治療用エピトープ並びにトランスジェニック植物
US9464120B2 (en) 2008-11-30 2016-10-11 Immusant, Inc. Compositions for treatment of celiac disease
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303871B2 (en) * 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
WO2004045392A2 (en) 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20070185021A1 (en) * 2004-01-09 2007-08-09 Scott Fraser W Diabetogenic epitopes
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
EP1755639B1 (en) * 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
WO2007105024A1 (en) * 2006-03-15 2007-09-20 Isocell Pharma S.A. Pharmaceutical compositions comprising sods and prolamine based peptide fragments
US7576040B2 (en) * 2007-01-11 2009-08-18 Halliburton Energy Services, Inc. Cement compositions comprising humic acid grafted fluid loss control additives
AU2008229448B2 (en) 2007-03-16 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
MX2010001734A (es) 2007-08-13 2010-08-04 Commw Scient Ind Res Org Cebada con bajos niveles de hordeinas.
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
KR20190087665A (ko) * 2011-01-20 2019-07-24 이뮤노사이언시스 랩. 인크. 글루텐 과민성 검출 및 만성소화장애증과의 구별 방법 및 장치
US20140037661A1 (en) * 2011-02-08 2014-02-06 Phadia Ab Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
WO2012162697A1 (en) * 2011-05-26 2012-11-29 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
US20160091491A1 (en) * 2013-05-02 2016-03-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
US20160145636A1 (en) * 2013-05-08 2016-05-26 Jm Biologicals Compositions and methods for the production of gluten free food products
WO2014191839A2 (en) * 2013-05-14 2014-12-04 Oslo Universitetssykehus Hf Detection of gluten-specific t-cells
NZ631602A (en) 2013-06-13 2019-09-27 Grains Res & Dev Corp Barley with very low levels of hordeins
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2015164747A1 (en) * 2014-04-24 2015-10-29 Immusant, Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
US10370718B2 (en) 2014-09-29 2019-08-06 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
EP3221344A2 (en) 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
DE102015204012A1 (de) 2015-03-05 2016-09-08 Clariant International Ltd. SCR-Katalysator mit verbesserter Haftung
EP3432877B1 (en) 2016-03-24 2023-01-11 ImmunoMolecular Therapeutics, Inc. D-alpha-methyldopa for treating autoimmune disease
CA3035484A1 (en) * 2016-09-01 2018-03-08 Cellectis Methods for altering amino acid content in plants
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
CN110128549B (zh) * 2019-05-27 2021-07-06 深圳市亚辉龙生物科技股份有限公司 脱酰胺基麦胶蛋白多肽重组抗原、重组抗原表达基因、重组表达载体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459355A (en) 1982-07-12 1984-07-10 International Paper Company Method for transforming plant cells
US4536475A (en) 1982-10-05 1985-08-20 Phytogen Plant vector
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
JPS6047683A (ja) 1983-08-24 1985-03-15 Kirin Brewery Co Ltd プロモ−タ−
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
DK162399C (da) * 1986-01-28 1992-03-23 Danisco Fremgangsmaade til ekspression af gener i baelgplanteceller, dna-fragment, rekombineret dna-fragment samt plasmid til brug ved udoevelsen af fremgangsmaaden
ES2018274T5 (es) 1986-03-11 1996-12-16 Plant Genetic Systems Nv Celulas vegetales resistentes a los inhibidores de glutamina sintetasa, preparadas por ingenieria genetica.
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5187073A (en) 1986-06-30 1993-02-16 The University Of Toledo Process for transforming gramineae and the products thereof
US5177010A (en) 1986-06-30 1993-01-05 University Of Toledo Process for transforming corn and the products thereof
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0267159A3 (de) 1986-11-07 1990-05-02 Ciba-Geigy Ag Verfahren zur genetischen Modifikation monokotyler Pflanzen
US4866247A (en) 1986-12-11 1989-09-12 The Lincoln Electric Company Apparatus and method of short circuiting arc welding
US4971908A (en) 1987-05-26 1990-11-20 Monsanto Company Glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthase
US5356799A (en) * 1988-02-03 1994-10-18 Pioneer Hi-Bred International, Inc. Antisense gene systems of pollination control for hybrid seed production
US5371014A (en) 1988-02-12 1994-12-06 Daicel Chemical Industries, Ltd. Process for the production of optically active 2-hydroxy acid esters using microbes to reduce the 2-oxo precursor
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5250515A (en) 1988-04-11 1993-10-05 Monsanto Company Method for improving the efficacy of insect toxins
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5428146A (en) * 1988-11-07 1995-06-27 Max-Planck-Gesellschaft Zur Forderung Wound-stimulated DNA-sequence from solanum tuberosum and its use
US5110732A (en) 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
US5086169A (en) 1989-04-20 1992-02-04 The Research Foundation Of State University Of New York Isolated pollen-specific promoter of corn
US5629183A (en) * 1989-05-08 1997-05-13 The United States Of America As Represented By The Secretary Of Agriculture Plant transformation by gene transfer into pollen
US5097025A (en) 1989-08-01 1992-03-17 The Rockefeller University Plant promoters
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
ATE160174T1 (de) 1989-08-09 1997-11-15 Dekalb Genetics Corp Methoden und zusammensetzungen für die herstellung von stabil transformierten, fruchtbaren mais pflanzen und zellen dafür
ES2215986T3 (es) * 1989-10-27 2004-10-16 The Salk Institute For Biological Studies Composiciones receptoras de glutamato y metodos.
US5589583A (en) * 1990-01-11 1996-12-31 Monsanto Company Plant promoter
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
HU220773B1 (hu) 1990-01-22 2002-05-28 Dekalb Genetics Corporation Eljárás termő transzgenikus kukoricanövények előállítására
EP0442174A1 (en) 1990-02-13 1991-08-21 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
US5618988A (en) 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5187267A (en) 1990-06-19 1993-02-16 Calgene, Inc. Plant proteins, promoters, coding sequences and use
WO1992000377A1 (en) 1990-06-25 1992-01-09 Monsanto Company Glyphosate tolerant plants
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
NZ239977A (en) 1990-11-14 1993-08-26 Pioneer Hi Bred Int Transforming plants by the use of agrobacterium
EP0559742A1 (en) 1990-11-26 1993-09-15 E.I. Du Pont De Nemours And Company Herbicidal oxazine ethers
US5459252A (en) 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
WO1992013957A1 (en) * 1991-02-07 1992-08-20 Plant Genetic Systems, N.V. Stamen-specific promoters from corn
IL101508A0 (en) 1991-04-08 1992-12-30 Rhone Poulenc Agrochimie Chimeric plant genes based on upstream regulatory elements of helianthinin
AU664034B2 (en) 1991-05-15 1995-11-02 Monsanto Company Method of creating a transformed rice plant
AU2515592A (en) 1991-08-23 1993-03-16 University Of Florida A novel method for the production of transgenic plants
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
WO1994010307A1 (en) 1992-10-29 1994-05-11 Medical Research Council Transcription factor dp-1
US5389226A (en) 1992-12-17 1995-02-14 Amorphous Technologies International, Inc. Electrodeposition of nickel-tungsten amorphous and microcrystalline coatings
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1994025613A1 (en) 1993-05-03 1994-11-10 Cornell Research Foundation, Inc. Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
US5670349A (en) * 1993-08-02 1997-09-23 Virginia Tech Intellectual Properties, Inc. HMG2 promoter expression system and post-harvest production of gene products in plants and plant cell cultures
CA2148499C (en) 1993-09-03 2006-07-11 Hideaki Saito Method for transforming monocotyledons using scutella of immature embryos
WO1995019030A1 (en) * 1994-01-05 1995-07-13 Pois, Inc. Apparatus and method for a personal onboard information system
US5495007A (en) 1994-04-29 1996-02-27 Thompson; Gary A. Phloem-specific promoter
US5459007A (en) * 1994-05-26 1995-10-17 Xerox Corporation Liquid developer compositions with block copolymers
US5633363A (en) 1994-06-03 1997-05-27 Iowa State University, Research Foundation In Root preferential promoter
US5646333A (en) * 1994-09-02 1997-07-08 Drexel University Plant promoter useful for directing the expression of foreign proteins to the plant epidermis
HUT76355A (en) 1995-11-24 1997-08-28 Bay Zoltan Alkalmazott Kutatas Plant gene-expression vector family based on dna fragments regulating alfalfa h3 histon gene variant (ms h3g1)
US6036983A (en) * 1996-05-20 2000-03-14 Novo Nordisk A/S Method of obtaining protein hydrolysates
CA2257972A1 (en) 1996-06-13 1997-12-18 Consejo Superior De Investigaciones Cientificas Plant proteins
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US5959175A (en) 1997-04-09 1999-09-28 Thomas; Terry L. Sunflower albumin 5' regulatory region for the modification of plant seed lipid composition
US5977436A (en) 1997-04-09 1999-11-02 Rhone Poulenc Agrochimie Oleosin 5' regulatory region for the modification of plant seed lipid composition
ES2132025B1 (es) 1997-06-12 2000-12-01 Consejo Superior Investigacion Proteinas urag de las plantas.
US6100450A (en) 1997-10-22 2000-08-08 Rhone-Poulenc Agrochimie Seed specific promoters based on arabidopsis genes
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
WO1999053069A2 (en) 1998-04-09 1999-10-21 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins cdc2 and pitslre from plants
AU3828099A (en) 1998-05-08 1999-11-29 Consejo Superior De Investigaciones Cientificas Transgenic plant cells expressing a recombinant plant e2f peptide
AU3230200A (en) 1999-02-12 2000-08-29 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
MXPA03009313A (es) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq.
DE60221700T2 (de) * 2001-12-11 2008-04-30 Tagsys S.A. Systeme zum sicheren markieren von daten
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7303871B2 (en) * 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
WO2004045392A2 (en) * 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7144567B2 (en) * 2002-12-16 2006-12-05 Erling Jim Andersen Renewable energy carrier system and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013126991A (ja) * 1999-10-01 2013-06-27 Isis Innovation Ltd 診断及び治療用エピトープ並びにトランスジェニック植物
US9464120B2 (en) 2008-11-30 2016-10-11 Immusant, Inc. Compositions for treatment of celiac disease
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition

Also Published As

Publication number Publication date
HK1088068A1 (en) 2006-10-27
ES2335895T3 (es) 2010-04-06
AU7539400A (en) 2001-05-10
US20080175971A1 (en) 2008-07-24
US20180057547A1 (en) 2018-03-01
JP2013126991A (ja) 2013-06-27
ES2256042T3 (es) 2006-07-16
CY1105282T1 (el) 2010-03-03
PT1218751E (pt) 2006-06-30
JP6139154B2 (ja) 2017-05-31
JP2010263898A (ja) 2010-11-25
JP2003511670A (ja) 2003-03-25
JP5371890B2 (ja) 2013-12-18
CA2386089C (en) 2016-06-21
US7144569B1 (en) 2006-12-05
DK1672368T3 (da) 2010-01-04
DE60043402D1 (de) 2010-01-07
CA2386089A1 (en) 2001-04-12
AU782262B2 (en) 2005-07-14
EP1218751A2 (en) 2002-07-03
DK1218751T3 (da) 2006-07-03
EP1672368B1 (en) 2009-11-25
ATE449965T1 (de) 2009-12-15
US20090269285A1 (en) 2009-10-29
GB9923306D0 (en) 1999-12-08
US8329144B2 (en) 2012-12-11
WO2001025793A3 (en) 2001-08-23
US7888460B2 (en) 2011-02-15
DE60026332T2 (de) 2006-08-10
MXPA02003295A (es) 2002-09-02
WO2001025793A2 (en) 2001-04-12
EP1672368A1 (en) 2006-06-21
PT1672368E (pt) 2010-01-20
US20130318648A1 (en) 2013-11-28
JP2016164169A (ja) 2016-09-08
ATE319091T1 (de) 2006-03-15
DE60026332D1 (de) 2006-04-27
US20110044912A2 (en) 2011-02-24
EP1218751B1 (en) 2006-03-01
CY1109837T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
JP4932112B2 (ja) 診断及び治療用エピトープ並びにトランスジェニック植物
JP5977293B2 (ja) 治療用エピトープ及びそれらの使用
CN102430111B (zh) 与腹部疾病有关的表位
HK1088068B (en) Diagnostic and therapeutic epitope
HK1205748B (en) Therapeutic epitopes and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120215

R150 Certificate of patent or registration of utility model

Ref document number: 4932112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250